We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

Type
Public
HQ
Brisbane, US
Founded
2011
Size (employees)
122 (est)+20%
Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US
Report incorrect company information

Key People/Management at Aimmune Therapeutics

Daniel C. Adelman

Daniel C. Adelman

Chief Medical Officer
Sue Barrowcliffe

Sue Barrowcliffe

General Manager of Europe
Eric Bjerkholt

Eric Bjerkholt

CFO
Jayson Dallas

Jayson Dallas

President and Chief Executive Officer
Becki Filice

Becki Filice

SVP, Product and Portfolio Management
Mary Rozenman

Mary Rozenman

SVP, Corporate Development and Strategy
Show more

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has offices in Greater London and Brisbane
Brisbane, US (HQ)
200 8000 Marina Blvd
Greater London, GB
344-354 Grays Inn Rd
Show all (2)
Report incorrect company information

Aimmune Therapeutics Financials and Metrics

Aimmune Therapeutics Financials

USD

Net income (Q1, 2018)

(49.5 m)

EBIT (Q1, 2018)

(50.1 m)

Market capitalization (14-Jun-2018)

1.7 b

Closing share price (14-Jun-2018)

29.8

Cash (31-Mar-2018)

209.3 m
Aimmune Therapeutics's current market capitalization is $1.7 b.
Annual
USDFY, 2015FY, 2016

General and administrative expense

16.2 m26.9 b

R&D expense

19.8 m54.6 b

Operating expense total

36 m81.5 b

EBIT

(36 m)(81.5 b)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

5.2 m5.7 m6.5 m6.4 m8.9 m10.8 m16.7 m

R&D expense

3.9 m10 m11.8 m15.9 m17.4 m22.2 m33.4 m

Operating expense total

9 m15.7 m18.3 m22.2 m26.3 m33 m50.1 m

EBIT

(9 m)(15.7 m)(18.3 m)(22.2 m)(26.3 m)(33 m)(50.1 m)
Annual
USDFY, 2015FY, 2016

Cash

76.7 m124 m

Inventories

5.6 m2.7 m

Current Assets

197.5 m251.7 m

PP&E

2.7 m10.4 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

58.5 m112.7 m65 m74.4 m76.9 m78.7 m84.5 m209.3 m

Current Assets

60.6 m217.8 m185.2 m172.8 m152.6 m248.9 m242.6 m330.3 m

PP&E

1.3 m1.8 m3.7 m7 m9 m11.1 m13.1 m21 m

Total Assets

62.1 m222.8 m199.9 m185.7 m173.7 m276.3 m256.4 m361.8 m
Annual
USDFY, 2015FY, 2016

Net Income

(35.8 m)(80.8 m)

Depreciation and Amortization

115 k534 k

Inventories

4 m

Accounts Payable

1.1 m(994 k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9 m)(15.5 m)(18.1 m)(22.1 m)(25.9 m)(49.5 m)

Depreciation and Amortization

356 k

Accounts Payable

309 k1 m1.8 m1.3 m1.5 m1.7 m(431 k)

Cash From Operating Activities

(39.8 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Aimmune Therapeutics Operating Metrics

FY, 2016

Patents Issued

2
Show all operating metrics
Report incorrect company information

Aimmune Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Aimmune Therapeutics News and Updates

Report incorrect company information